A comprehensive view of Approval Recommendations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

NH SB560: Establishing a committee to study pharmacy benefit manager operations' impact on prescription drug costs and distribution.
Published: May 09, 2024 by New Hampshire 2024 Regular Session
European Medicines Agency validates Bristol Myers' application for Opdivo nivolumab plus Yervoy ipilimumab for the first-line treatment of adult patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer
Published: May 06, 2024 by Bristol-Myers Squibb Co.
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
Published: May 05, 2024 by Janssen Pharmaceutical Companies
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
Published: May 03, 2024 by Janssen Pharmaceutical Companies
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Published: May 02, 2024 by Benzinga Lightning Feed

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count